you forgot to mention that SNY has reached out only to a handful of doctors; thus, there has NOT been any effort made to sell Afrezza.
you sir think just like I do! The tree shaking is convincing and vigorous, most monkeys have fallen off the tree. Either I am too stubborn refusing to see the obvious or too coniving to believe the hidden agenda.
your bankruptcy yes! mnkd NO! It will be sold to another BP or SNY.
along with his recovery from illness, Mann does a slow controlled launch that traps the shorts to 120 million shares. While his friends in Isreal are guaranteed shares in the $2 range; none for the shorts to buy back and cover (a strong message to the shorts that if they want to cover, they would have to buy back from the market). Then comes the news that will cause an Epic short squeeze like KBIO, 4000%
Strange how Al Mann just stepped down and gave the CEO position to Hakan, where he essentially did nothing for the last year and half. Perhaps Mann needed surgery and recovery for the last year and half. NOw he is ready to tackle his duty as CEO/founder. AT 89, alot can go wrong with your body and requiring surgery is very common.
Mnkd/ Afrezza is his baby. Perhaps he knew that the launch would be slow and he decided to take a year of rest and allowed Hakan to play the role but never really acted upon the role. Now that Afrezza is about to get its glory, Alfred Mann steps back in to obtain that glory. Being the chairman and the founder would have earned him great recognition regardless but Mann wants to prevent any confusion who the man is behind this legacy. I am expecting fireworks from this point on.
SNY can sand bag Afrezza all they want but eventually they know they have to counter bid. Alfred Mann will have to come up with an offer before January to put pressure on SNY.
and if you were SNY, you would behave just like the way SNY has been behaving, which is not to put too much effort on the launch. The more you want it, the more sand bagging of Afrezza.
hammer, it could be SNY, that option is always available to them. But the reason where the expenses are kept to a minimum is to cap the initial launch expense, then present it to interest buyer(s). Now the biddings can begin. They will have additional studies to present to buyers.
the partnership deal left alot undisclosed to the public. Greenhill required more than a year to come up with this simple partnership; there has to be more than this.
secrets are usually not reflected on share price. If Al Mann wanted to burn the shorts, he would see to it, that is kept a secret.
that fact that SNY hasn't done jacksheet or spent any money suggests that their role was just to get the ball rolling on the insurance approval and some loans. The sales effort is more like a gift from SNY if they have only approached less than 100 docs. The cost and loans are easily tabulated.
A buyer was already inked since June of 2014 after FDA approval. SNY was only contracted to start off the launch and the buyer will reimburse the expenses initiated by SNY. That would be the most clever short trap ever!!!!
such a large market with abundant docs, all they have to do is capture a meager 1% of the market and it will be a blockbuster. Unbelievable the degree of sand bagging.....Maybe Al mann is asking for $50 billion!!!!
Am I suppose to believe that number? 1/10 people on the planet has diabetes, and even more common among the patient population. Each family doc sees about 20-60 patients per day, at least 2-3 requires insulin at mealtime. Internists each sees about 10-20 patients, among the sickest patients, at least 1-2 needs insulin at meal time. So SNY is trying to convince us that they are only getting 500 scripts/wk???!!! Stop the BSing and start selling Afrezza. They would have to pry the shares out of my dead hands.
500,000 docs in the US capable of writing prescription for Afrezza, if only each is writing ONE each week, which is a very low estimate, mnkd would be a $50 billion dollar company. You have to pry the shares out of my dead hands.
it's both sand bagging and controlled. They are reaching out to only less than 100 docs who have been prescribing Afrezza since the launch; the script # has not changed week after week-- this is VERY apparent. They are collecting data on retention rate and renewals, conducting studies on HbA1c and peds. Unfortunate for mnkd, while they are doing this the script #/revenue from Afrezza do not meet milestones; hence, they do not get milestone payments. This puts mnkd in financial hardship; thus, this is a sand bagging part.
expecting major changes before January 2016, either a bid for mnkd or TS project announcement partner. Once TS partnership is established, buyout is highly unlikely with any other companies except with that partner.